The Power Of Pradaxa: Physicians Weigh In
Executive Summary
With the worldwide market for novel oral anti-coagulants Pradaxa, Xarelto, and apixiban pegged at as much as $10 billion, how these drugs fare with physicians - and, importantly, payors - provides a case study for future big drug launches in an era where health care costs are a key consideration.
You may also be interested in...
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.